Tetrastatin, the NC1 domain of the α4(IV) collagen chain: A novel potent anti-tumor matrikine

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Brassart Pasco, Sylvie ^a   Sénéchal, Karine ^a   Thevenard, Jessica ^a   Ramont, Laurent ^a,b   Devy, Jérome ^a   Di Stefano, Ludivine ^a   Dupont Deshorgue, Aurélie ^a   Brézillon, Stéphane ^a   Feru, Jezabel ^a   Jazeron, Jean François ^b   Diebold, Marie Danièle ^b   Ricard Blum, Sylvie ^c   Maquart, François Xavier ^a,b   Monboisse, Jean Claude ^a,b  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; MATRIX METALLOPROTEINASE; MELATONIN 1 RECEPTOR; NYSTATIN PLUS TETRACYCLINE; RECOMBINANT PROTEIN; VITRONECTIN RECEPTOR; ANTIBODY; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER SIZE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; ENZYME ACTIVATION; ENZYME LOCALIZATION; ENZYME MODIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SKIN FIBROBLAST; TUMOR XENOGRAFT; ANIMAL; CELL MOTION; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PROTEIN TERTIARY STRUCTURE; SURFACE PLASMON RESONANCE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE IV; HUMANS; INTEGRIN ALPHAVBETA3; MATRIX METALLOPROTEINASES; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84859949978     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029587     Document Type: Article

References (41)

1. Itoh H, Seiki M, (2006) MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 206: 1-8.
2. Seiki M, (2003) Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 194: 1-11.
3. Brooks PC, Stromblad S, Sanders, Von Schalscha TL, Aimes RT, et al. (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin α v β 3. Cell 85: 683-693.
4. Labrecque L, Nyalendo C, Langlois S, Durocher Y, Roghi C, et al. (2004) Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem 279: 52132-52140.
5. Yamaguchi H, Takeo Y, Yoshida S, Kouchi Z, Nakamura Y, et al. (2009) Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. Cancer Res 69: 8594-8602.
6. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG, (2003) Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 348: 2543-2556.
7. Zhou J, Ding M, Zhao ZH, Reeders ST, (1994) Complete primary structure of the sixth chain of human basement membrane collagen, α6(IV). Isolation of the cDNAs for α6(IV) and comparison with five other type IV collagen chains. J Biol Chem 269: 13193-13199.
8. Kalluri R, (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3: 422-433.
9. Mundel TM, Kalluri R, (2007) Type IV collagen-derived angiogenesis inhibitors. Microvasc Res 74: 85-89.
10. Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, et al. (2000) Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60: 2520-2526.
11. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, et al. (2000) Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275: 1209-1215.
12. Pasco S, Ramont L, Venteo L, Pluot M, Maquart FX, et al. (2004) In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. Exp Cell Res 301: 251-265.
13. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, et al. (2000) Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275: 21340-21348.
14. Mundel TM, Yliniemi AM, Maeshima Y, Sugimoto H, Kieran M, et al. (2008) Type IV collagen alpha 6 chain-derived noncollagenous domain 1 (alpha6(IV)NC1) inhibits angiogenesis and tumor growth. Int J Cancer 122: 1738-1744.
15. Petitclerc E, Boutaud A, Prestayko A, Xu J, Sado Y, et al. (2000) New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 275: 8051-8061.
16. Pasco S, Monboisse JC, Kieffer N, (2000) The alpha 3(IV)185-206 peptide from non collagenous domain 1 of type IV collagen interacts with a novel binding site on the beta 3 subunit of integrin alpha V beta 3 and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation. J Biol Chem 275: 32999-33007.
17. Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, et al. (2001) Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J Biol Chem 276: 31959-68.
18. Magnon C, Galaup A, Mullan B, Rouffiac V, Bouquet C, et al. (2005) Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res 65: 4353-4361.
19. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, et al. (2003) Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3: 589-601.
20. Pedchenko V, Zent R, Hudson BG, (2004) Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelial cell adhesion. J Biol Chem 279: 2772-80.
21. Trent JM, Stanbridge EJ, McBride HL, Meese EU, Casey G, et al. (1990) Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 247: 568-571.
22. Wald M, Olejar T, Sebkova V, Zadinova M, Boubelik M, et al. (2001) Mixture of trypsin, chymotrypsin, and papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngenic melanoma B16. Cancer Chemother Pharmacol 47: 16-22.
23. Faye C, Moreau C, Chautard E, Jetne R, Fukai N, et al. (2009) Molecular interplay between endostatin, integrins, and heparan sulfate. J Biol Chem 284: 22029-22040.
24. Montgomery AM, De Clerck YA, Langley KE, Reisfeld RA, Mueller BM, (1993) Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 53: 693-700.
25. Meissauer A, Kramer MD, Schirrmacher V, Brunner G, (1992) Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Exp Cell Res 199: 179-90.
26. Hofmann UB, Houben R, Bröcker EB, Becker JC, (2005) Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 87: 307-14.
27. Chelberg MK, Tsilibary EC, Hauser AR, McCarthy JB, (1989) Type IV collagen-mediated melanoma cell adhesion and migration: involvement of multiple, distinct domains of the collagen molecule. Cancer Res 49: 4796-4802.
28. Maquoi E, Frankenne F, Noël A, Krell HW, Grams F, et al. (2000) Type IV collagen induces matrix metalloproteinase 2 activation in HT1080 fibrosarcoma cells. Exp Cell Res 261: 348-359.
29. Pasco S, Ramont L, Maquart FX, Monboisse JC, (2004) Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol Hematol 49: 221-233.
30. Maeshima Y, Manfredi M, Reimer C, Holthaus KA, Hopfer H, et al. (2001) Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 276: 15240-15248.
31. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, et al. (2002) Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295: 140-3.
32. Pasco S, Han J, Gillery P, Bellon G, Maquart FX, et al. (2000) A specific sequence of the noncollagenous domain of the alpha3(IV) chain of type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells. Cancer Res 60: 467-73.
33. Floquet N, Pasco S, Ramont L, Derreumaux P, Laronze JY, (2004) The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent. J Biol Chem 279: 2091-100.
34. Thevenard J, Floquet N, Ramont L, Prost E, Nuzillard JM, et al. (2006) Structural and antitumor properties of the YSNSG cyclopeptide derived from tumstatin. Chem Biol 13: 1307-1315.
35. Thevenard J, Ramont L, Devy J, Brassart B, Dupont-Deshorgue A, et al. (2010) The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration. Int J Cancer 126: 1055-1066.
36. Karagiannis ED, Popel AS, (2007) Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties. Biochem Biophys Res Commun 354: 434-439.
37. Seiki M, (2002) The cell surface: the stage for matrix metalloproteinase regulation of migration. Curr Opin Cell Biol 14: 624-632.
38. Barbolina MV, Stack MS, (2008) Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol 19: 24-33.
39. Shahan TA, Ziaie Z, Pasco S, Fawzi A, Bellon G, et al. (1999) Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells. Cancer Res 59: 4584-4590.
40. Maeshima Y, Colorado PC, Kalluri R, (2000) Two RGD-independent alpha v beta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275: 23745-23750.
41. Sudhakar A, Nyberg P, Keshamouni VG, Mannam AP, Li J, et al. (2005) Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. J Clin Invest 115: 2801-2810.